Cystic fibrosis

Cystic fibrosis (CF) is an inherited disease that affects nearly 30,000 Americans.1  

The metabolic abnormalities associated with CF result in the production of large quantities of thick, sticky mucus that often contains infection-causing bacteria and lung tissue-destroying inflammatory byproducts. To minimize the risk of recurrent infection, bacterial colonization and progressive lung disease, daily airway clearance therapy (ACT) is a medically necessary standard of care for all CF patients.2

The Philips InCourage system – helps CF patients breathe easier


The InCourage system is a high-frequency chest wall oscillation (HFCWO) device—more commonly called vest therapy. It uses triangular waveform technology, which research has shown clears up to 20% more mucus than competing technology.3
The Philips InCourage system

HFCWO: a standard of care for U.S. patients with CF4
HFCWO: a standard of care for U.S. patients with CF

 

  • More than 75% of American CF patients use vest therapy. 5
  • CF is an expensive condition to treat relative to other chronic disorders.6 
  • CF patients have annual medical care expenditures of $48,098 – 22 times higher than for a cohort without CF.6 
  • Over a two-year period, vest therapy was shown to contribute to a 50% reduction in total healthcare costs for these patients.7
Vest icon
Live is very busy and needs to be as uncomplicated as possible when you’re learning to live with CF. Being able to throw the vest in the washing machine and not have to worry about durability is vital.

Lisa W., SC

References

1. Cystic Fibrosis Foundation Patient Registry 2017 Annual Data Report Bethesda, Maryland ©2018 Cystic Fibrosis Foundation, p. 6.​
2. Kluft J, Beker L, Castagnino M, Gaiser J, Chaney H, Fink R. A comparison of bronchial drainage treatments in cystic fibrosis. Pediatr Pulmonol 1996; 22: 271-27.​
3. Milla CE, Hansen LG, Weber A, Warwick WJ. High-Frequency chest compression: effect of the third generation compression waveform. Biomed Instrum Technol 2004; 38:322-328. Note: 8 CF patient study comparing triangular vs. sine waveform technology.​
4. Nicolini A, Cardini F, Landucci N, Lanata S, Ferrari-Bravo M, Barlascini C. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC Pulm Med 2013; 13:21.​
5. Cystic Fibrosis Foundation Patient Registry 2017 Annual Data Report Bethesda, Maryland ©2018 Cystic Fibrosis Foundation, p. 58.​
6. Ouyang L, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009; 44: 989-996.​
7. Ohnsorg F. A cost analysis of high-frequency chest wall oscillation in cystic fibrosis. Am J Resp and Crit Care Med 1994; Suppl 149(4): A669.​
Respitech
5905 Nathan Lane North, Suite 200, Plymouth, MN 55442
©2019 Koninklijke Philips N.V. All rights reserved.